Browsing by Author "Fountzilas, George"
Now showing items 21-40 of 141
-
Article
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study
Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...
-
Article
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results
Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...
-
Article
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
Briassoulis, E. Ch; Tsavaris, N.; Fountzilas, George; Athanasiades, A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Pavlidis, Nicholas (1998)The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
-
Article
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...
-
Article
DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study
Bamias, A. T.; Fountzilas, George; Michael, M. C.; Konstantaras, C.; Vrettou, E.; Eleftheriadis, E.; Papakostas, P.; Papadimitriou, K.; Pavlidis, Nicholas; Xiros, N.; Bai, M. C. (2008)There is a high risk of relapse after resection of gastric cancer. We studied the prognostic significance of the deleted colorectal cancer (DCC) gene and thymidylate synthase (TS) protein expression after resection of ...
-
Article
Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
Nikolaides, C.; Fountzilas, George; Zoumbos, N.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Pectasides, Dimitrios; Karabelis, A.; Giannakakis, T.; Symeonidis, A.; Papadopoulos, A.; Antoniou, F.; Pavlidis, Nicholas (1998)Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently ...
-
Article
Do LH-RH analogues induce effects similar to tamoxifen on serum lipid parameters in premenopausal women with breast cancer? A prospective study
Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Fountzilas, George; Tzallas, C. S.; Tsolas, O.; Siamopoulos, K. C.; Pavlidis, Nicholas (1998)Background and Aim: As a continuation of our investigational program we carried out the present study to evaluate and compare the impact of LH-RH analogues and tamoxifen on serum lipid parameters in premenopausal women ...
-
Article
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study
Pentheroudakis, George; Briassoulis, E. Ch; Kalofonos, H. P.; Fountzilas, George; Economopoulos, T.; Samelis, G.; Koutras, A. K.; Karina, M.; Xiros, N.; Samantas, E.; Bamias, A. T.; Pavlidis, Nicholas (2008)Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...
-
Article
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
Skarlos, Dimosthenis V.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Papakostas, P.; Pavlidis, Nicholas; Bacoyiannis, Charalambos; Kiamouris, Ch; Klouvas, G. D.; Gogas, H.; Fountzilas, George; Samantas, E. (2003)There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part ...
-
Article
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study
Fountzilas, George; Nikolaides, C.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Samelis, G.; Aravantinos, Gerasimos; Pavlidis, Nicholas (2000)A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...
-
Article
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
Fountzilas, George; Nikolaides, C.; Aravantinos, Gerasimos; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, Dimitrios; Pavlidis, Nicholas (1998)Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
Razi, E. D.; Dimopoulos, M. A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Briassoulis, E. Ch; Samantas, E.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Fountzilas, George (2001)The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group
Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...
-
Article
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
Briassoulis, E. Ch; Pappas, P.; Puozzo, C.; Ch, F. Tolis; Fountzilas, George; Dafni, U.; Marselos, M.; Pavlidis, Nicholas (2009)Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...
-
Article
Elderly patients with squamous lung carcinoma: Faring better or worse?
Pentheroudakis, George; Neanidis, K.; Kostadima, Lida; Fountzilas, George; Pavlidis, Nicholas (2006)Introduction: Nonsmall cell lung cancer is increasingly diagnosed at an advanced age and squamous cell carcinoma is the commonest histological type encountered in older patients. The clinical course, management, and outcome ...
-
Article
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
Pectasides, Dimitrios; Papaxoinis, G.; Fountzilas, George; Aravantinos, Gerasimos; Bamias, A. T.; Pavlidis, Nicholas; Kalofonos, H. P.; Timotheadou, E.; Samantas, E.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Economopoulos, T.; Dimopoulos, M. A. (2009)Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
-
Article
Evaluation of six tumor markers in patients with carcinoma of unknown primary
Pavlidis, Nicholas; Kalef-Ezra, J. A.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Saferiadis, K.; Bairaktari, Eleni Th; Bafaloukos, Dimitrios; Maravegias, A.; Theoharis, D.; Fountzilas, George (1994)We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...